secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-08-22T23:59:59+00:00
Accession:  0001193125-24-205405
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin R&D chief Henry Fuchs to retire March 2025; Greg Friberg to succeed
----------------------------------------------------------------------------

- Dr. Henry J. Fuchs to retire from BioMarin effective March 3, 2025.
- Dr. Greg Friberg to assume EVP, Chief Worldwide R&D Officer role on September 30, 2024.
- Fuchs will serve as senior advisor from October 1, 2024 until retirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/d880241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-205405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer